- Dabigatran
-
-
2026-10-18
- CAS:211914-51-1
- Purity: 0.99
- Dabigatran
-
- $5.00
-
2026-09-02
- CAS:211914-51-1
- Min. Order: 1KG
- Purity: 99%
- Dabigatran
-
-
2026-09-01
- CAS:211914-51-1
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 20tons
|
| | Dabigatran Basic information |
| | Dabigatran Chemical Properties |
| Melting point | 268-272°C | | Boiling point | 797.1±70.0 °C(Predicted) | | density | 1.38±0.1 g/cm3(Predicted) | | storage temp. | Keep in dark place,Inert atmosphere,Room temperature | | solubility | Aqueous Acid | | form | Solid | | pka | 4.17±0.10(Predicted) | | color | White to Brown | | InChIKey | YBSJFWOBGCMAKL-UHFFFAOYSA-N | | SMILES | C(O)(=O)CCN(C(C1=CC=C2N(C)C(CNC3=CC=C(C(N)=N)C=C3)=NC2=C1)=O)C1=NC=CC=C1 |
| | Dabigatran Usage And Synthesis |
| Chemical Properties | Tan Solid | | Uses | Nonpeptide, direct thrombin inhibitor. Antithrombotic. | | Uses | BIBR 953 (Dabigatran, Pradaxa) is potent nonpeptide thrombin inhibitor with an IC50 of 9.3 nM | | Definition | ChEBI: An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amoino group of N-pyridin-2-yl-b
ta-alanine. The active metabolite of the prodrug dabigatran etexilate, it acts as an anticoagulant which is used for the prevention of stroke and systemic embolism. | | Biological Activity | bibr 953 is a potent, reversible, and direct inhibitor of thrombin with ic50 value of 9.3nm [1].bibr 953 shows a favorable selectivity profile and strong activity in vitro with a ki value of 4.5nm. it also exhibits the best activity profile in vivo following administration to rats. bibr 953 is designed to be converted into an orally active prodrug bibr 1048 due to its highly polar, zwitterionic nature and poor oral absorption. bibr 953 inhibits thrombin in a competitive fashion. this inhibition is rapid and reversible. bibr 953 inhibits both clot-bound and free thrombin. bibr 953 is demonstrated to have an anticoagulant efficacy both in vitro and ex vivo. since thrombin can affect cell behavior and response in various tissue types via par signaling, bibr 953 is found to be beneficial in many diseases including inflammation, infection, fibrosis and cancer. | | target | thrombin | | references | [1] hauel nh, nar h, priepke h, ries u, stassen jm, wienen w. structure-based design of novel potent nonpeptide thrombin inhibitors. j med chem. 2002 apr 25;45(9):1757-66.
[2] van ryn j, goss a, hauel n, wienen w, priepke h, nar h, clemens a. the discovery of dabigatran etexilate. front pharmacol. 2013 feb 12;4:12. |
| | Dabigatran Preparation Products And Raw materials |
|